Please login to the form below
GSK loses Viani patent case in Germany
The Federal Patents Court in Germany has ruled against GlaxoSmithKline regarding its patent for Viani, a treatment for asthma and COPD
The Federal Patents Court in Munich, Germany has ruled against GlaxoSmithKline (GSK) regarding its patent for Viani (Seretide), an inhaled respiratory treatment for asthma and chronic obstructive pulmonary disease (COPD).
Mylan, Hexal (part of Novartis' Sandoz), Neolab, and IVAX (owned by Teva) brought the case against GSK to Court.
The Court concluded that under German law GSK's German combination patent for Viani (relating to the combination of the active ingredients salmeterol and fluticasone propionate) was not valid.
GSK is studying the judgment and will be considering an appeal to a higher court.
In a statement, GSK said that "the decision relates solely to the German combination patent for Viani and is not binding in any other jurisdiction".
GSK holds a number of other Viani-related patents in Germany, including patents for the Diskus dry powder inhaler and HFA aerosol formulation, which expire in 2011 and 2012, respectively.
Viani is also known as Advair in other markets. In 2009, the drug accounted for 18 per cent of GSK's revenue and posted sales of $7.8bn.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- EU secures 405 million doses of CureVac’s COVID-19 vaccine
- Pfizer, Mylan move ahead with generics merger and spin-out
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
- Send Us a Message
- Laurence Bannister joins Lucid Group as its new Chief Commercial Officer
- AZ’s COVID-19 vaccine demonstrates efficacy rate of up to 90%
- UK could approve Pfizer’s COVID-19 vaccine this week
- Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval
- Power to the patient: digital innovation supporting patients with chronic diseases
- New from the PhRMA: Diversity in clinical trials principles summarised
PMHub
AMICULUM Limited
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...
Latest intelligence
- New from the PhRMA: Diversity in clinical trials principles summarised
- In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
- New from the FDA: Diversity in clinical trials guidance summarised
- In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
- 5 steps to effective clinical trial branding
- When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...
Quick links
Infographics
